Drug intelligence / Profile preview

VLV based Vaccine

Development stage: Unknown
Lead developer: CaroGen
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Unknown

Overview

VLV based Vaccine is an investigational vaccine platform developed by CaroGen. "VLV" stands for Virus-Like Vesicle, a proprietary technology designed to deliver antigens and stimulate robust immune responses. The vaccine utilizes virus-like vesicles as carriers to present specific antigens to the immune system, aiming to induce both humoral and cellular immunity against targeted diseases. This approach is being explored for its potential in infectious disease prevention and cancer immunotherapy[1]. The primary mechanism involves mimicking viral infection without using live or attenuated viruses, thereby enhancing safety while maintaining strong immunogenicity.

Targets

HBV antigens (Hepatitis B virus antigens)

Beyond the preview

Go deeper on VLV based Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VLV based Vaccine.

Explore the full profile